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Abstract 
Background: Endogenous sex hormones are well established risk factors for breast cancer; the 
contribution of specific estrogen metabolites (EMs) and/or ratios of specific EMs is less clear. We 
have previously identified a CYP3A7*1C allele that is associated with lower urinary estrone (E1) levels 
in premenopausal women. The purpose of this analysis was to determine whether this allele was 
associated with specific pathway EMs. 
Methods: We measured successfully 12 EMs in mid-follicular phase urine samples from 30 
CYP3A7*1C carriers and 30 non-carriers using HPLC-MS/MS. 
Results: In addition to having lower urinary E1 levels, CYP3A7*1C carriers had significantly lower 
levels of four of the 2-hydroxylation pathway EMs that we measured (2-hydroxyestrone, P=1.1x10-12; 
2- hydroxyestradiol, P=2.7x10-7; 2-methoxyestrone, P=1.9x10-12, 2-methoxyestradiol, P=0.0009). By 
contrast, 16α-hydroxylation pathway EMs were slightly higher in carriers and significantly so for 17-
epiestriol (P=0.002). 
Conclusions: The CYP3A7*1C allele is associated with a lower urinary E1 levels, a more pronounced 
reduction in 2-hydroxylation pathway EMs and a lower ratio of 2-hydroxylation:16α-hydroxylation 
EMs in premenopausal women. To further characterise the association between parent estrogens, 
EMs and subsequent risk of breast cancer, characterisation of additional genetic variants that 
influence estrogen metabolism, and large prospective studies of a broad spectrum of EMs will be 
required. 
(199 words) 
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Introduction 
Endogenous sex hormones are well established risk factors for breast cancer. Pooled analyses of 
data from prospective studies have estimated that a doubling of circulating estradiol (E2), free E2 or 
estrone (E1) is associated with a 20-30% or 30-50% increase in breast cancer risk in pre- and 
postmenopausal women, respectively (Key et al, 2002; Key et al, 2013). The contribution of specific 
estrogen metabolites (EMs) to breast cancer risk is less clear. Briefly, interconversion between the 
parent estrogens, E2 and E1 occurs by reversible oxidation at the 17α-position of the steroid ring; 
conversion of parent estrogens to EMs is by irreversible hydroxylation at the 2-, 4- or 16-positions 
(Figure 1 (Badawi et al, 2001; Samavat & Kurzer, 2015; Tsuchiya et al, 2005)).  A recent review, 
summarising evidence from four prospective studies of estrogen metabolism and breast cancer risk, 
concluded that there was consistent evidence that enhanced 2-hydroxylation was associated with a 
reduction in risk of breast cancer that was independent of the strong positive associations of 
unconjugated parent estrogens (E2 and E1) with breast cancer risk (Ziegler et al, 2015). 
In an analysis of single nucleotide polymorphisms (SNPs) tagging genes that are involved in estrogen 
synthesis and metabolism we identified one SNP, rs10273424, that was associated with a 22% 
reduction in levels of urinary estrone glucuronide (E1G) in premenopausal women (Johnson et al, 
2012). rs10273424 maps to the cytochrome P450 3A (CYP3A) gene cluster at 7q22.1; the CYP3A 
genes (CYP3A5, CYP3A7 and CYP3A4) encode enzymes that catalyze the oxidative metabolism of a 
wide range of exogenous and endogenous substrates including parent estrogens (E1 and E2; Figure 
1). The metabolic capacity of the CYP3A enzymes differ, depending on the substrate (Williams et al, 
2002); with respect to estrogen metabolism specifically, 2-hydroxylation of E1 to 2-OHE1 is catalysed 
by CYP3A4, 4-hydroxylation to 4-OHE1 is catalysed by CYP3A4 and CYP3A5 and 16α-hydroxylation to 
16α-OHE1 is catalysed by CYP3A4, CYP3A5 and CYP3A7 (Figure 1; (Badawi et al, 2001; Lee et al, 2003; 
Tsuchiya et al, 2005)). Fine-mapping of the 7q22.1 association signal for urinary E1G levels implicated 
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the CYP3A7*1C allele as the causal allele (Johnson et al, 2016). This allele, which comprises seven 
highly correlated single base changes mapping to the CYP3A7 promoter, results in expression of the 
fetal CYP3A7 gene in adult carriers of the CYP3A7*1C allele (Burk et al, 2002; Gonzalez, 1988; Kuehl 
et al, 2001).  
 
The purpose of this current analysis was to determine whether, in addition to the association 
between CYP3A7*1C carrier status and lower urinary E1G levels, the CYP3A7*1C allele was 
associated with a reduction in levels of specific pathway EMs. 
 
Materials and methods 
Study population 
The study population from which the women we included in this analysis were drawn has been 
described previously (Johnson et al, 2012). Briefly, they comprised 729 premenopausal women who 
were first-degree relatives and friends of breast cancer cases participating in the British Breast 
Cancer study (Johnson et al, 2005) or participants in the intervention arm of a trial of annual 
mammographic screening in young women conducted in Britain (Mammography Oestrogens and 
Growth factors study (Walker et al, 2009)). To be eligible women had to be having regular menstrual 
cycles, not using hormone replacement therapy or oral contraceptives and not to have been 
diagnosed with breast cancer at recruitment to the study. All women were of self-reported White 
British ancestry. To be included in the original analysis and this subsequent analysis, women had to 
have provided serial urine samples (six follicular phase and one luteal phase), at pre-specified days 
of their menstrual cycle for measurement of creatinine adjusted urinary E1G using an in-house 
enzyme-linked immunosorbent assay (Johnson et al, 2012).  To maximise the statistical efficiency of 
this analysis of the CYP3A7*1C allele, which has a minor allele frequency (MAF) of just 4% in 
Northern European populations (Johnson et al, 2016), we selected 60 women on the basis of 
genotype; a random sample of 30 CYP3A7*1C carriers and 30 CYP3A7*1C non-carriers. We further 
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selected the two periovulatory samples (samples three and four of the six sequential follicular phase 
samples) on the basis that estrogen levels would be at their peak in these samples and this would 
maximise any differences in levels between CYP3A7*1C carriers and non-carriers. To minimise 
random variation, we used the average of these two sequential samples as our outcome variable.  
 
Ethics 
The study was conducted in accordance with the tenets of the Declaration of Helsinki and all 
participants provided written informed consent. 
 
Genotyping 
Genotyping of the tag SNP rs45467892, which is perfectly correlated with the CYP3A7*1C allele has 
been described previously (Johnson et al, 2016). Briefly, genotyping was by Taqman (Life 
Technologies, Paisley, UK). The call rate was 96.9% and concordance between duplicate samples was 
100%. 
 
HPLC-MS/MS analysis 
LC-MS/MS analysis was carried out for 14 EMs using the method of Xu and colleagues (Xu et al, 
2007; Xu et al, 2005). We were unable to measure one of the 15 EMs measured by Xu and colleagues 
(16-Epiestriol) as there was no commercially available standard for this EM. 
Briefly, two aliquots of frozen urine per woman were sent to the Mass Spectroscopy Facility for 
Quantitative Analysis, Faculty of Natural Science, Imperial College, London for analysis. Hydrolysis of 
glucuronide and sulfate conjugated EMs to form free EMs was carried out by mixing 500ul of freshly 
thawed urine with 20ul of internal standards (comprising 2ng of each of five deuterium-labelled 
estrogen metabolites (d-EMs); 17β-estradiol-d4, estriol-d3, 2-hydroxy-17β-estradiol-d5, 2-methoxy-
17bestradiol-d5 and 16-epiestriol-d3; Qmx Laboratories Ltd, UK) and 500ul of freshly prepared 
enzymatic hydrolysis buffer (100 µL of β-glucuronidase from Helix pomatia (Type H-2; Sigma-Aldrich) 
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in 10mL 0.15M sodium acetate buffer, pH4.6 containing 2 mg of ascorbic acid). Samples were 
incubated at 37oC overnight before extraction with dichloromethane and dansyl chloride 
dervitazation. The final derivatized samples (200 µL) were transferred to HPLC vials. Urine samples 
were randomly allocated to one of six analytical batches. Each batch contained one matrix blank, 
one matrix blank spiked with internal standards, eight-point calibration standards, three quality 
control (QC) samples and twenty urine samples. QC samples were prepared using charcoal stripped 
human urine (Golden West Biological Inc., CA, USA) with no detectable levels of estrogen 
metabolites, spiked with all 14 EMs at a concentration of 2ng/ml.   
Samples (10 μl) were then analysed by HPLC-electrospray ionisation/MS-MS using an Agilent 1100 
HPLC coupled to an SCIEX QTRAP 6500 mass spectrometer (SCIEX, California, USA) running in 
multiple reaction monitoring (MRM) mode. Chromatographic separation was carried out on a 
Phenomenex Synergi Hydro-RP 4 μm x 150 mm × 2.0 mm column, at 40°C. The solvent gradient used 
was 35%A (99.8% H2O: 0.2% CHOOH) to 85%B (99.8% MeOH: 0.2% CHOOH) over 60 min. Solvent B 
was held at 85% for 4 min then the solvent returned to 35% A for 10 min equilibration prior to the 
next injection. The solvent flow rate was 250 μl/min. The ESI source (type: Ion Drive Turbo V) 
parameters were set to - TEM 500oC, Curtain Gas 45psi, GS1 50psi, GS2 60psi, MS parameters were 
CAD gas Medium, DP 80, EP 10, CE 45, CXP 5. A scheduled detection method was used, the MRM 
detection window was 120 sec with a target scan time of 1 sec. Transitions and retention times are 
listed in Supplementary Table 1. 
Analyst® 1.6.2 software was used for quantitation of the EMs. Peak quantitations were carried out 
using deuterium labelled-EM internal standards and constructing matrix matched (charcoal stripped 
human urine) 8-point calibration curves for each of the six analytical batches. The calibration curves 
were evaluated by plotting the peak area ratios of dansyl-EM/d-dansyl-EM against concentration 
(ng/mL) of EMs in the standard and using linear regression with 1/X weighting to fit the data. Using 
this linear function, the amounts of EMs in the urine sample were interpolated.  
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The intra- and inter-batch coefficients of variation (CVs), evaluated from three QC samples per 
analytical batch, in six independent consecutive batches (N=18 QC samples) ranged from 6% to 10% 
(intra-batch CV) and 6% to 14% (inter-batch CV; Supplementary Table 2). The two highest inter-batch 
CVs were for 4-methoxyestrone (14%) and 4-methoxyestradiol (13%), the two estrogen metabolites 
that had the lowest concentrations and which were subsequently excluded from the analysis.  The 
LLOQ was estimated as 80 pg/mL, where the intra- and inter-batch precision of all the EMs were 
consistently less than 10% and the intra- and inter batch accuracies were between 97 and 105%. The 
LOD for the entire assay (all 14 EMs) was estimated to be 8 pg/mL. 
 
Statistical analysis 
EMs were converted from nanograms per ml of urine to picomoles per mg creatinine (pmol/mg) 
using the molecular weight of the unconjugated form of each of the EMs and the amount of 
creatinine (measured in mg/ml) for each of the samples. This allowed us to create pathway variables 
as described by Faupel-Badger and colleagues (Faupel-Badger et al, 2010). Where both of the two 
samples per woman were measured successfully we used the mean of the two measurements, 
where one of two measurements from a woman was missing, we used the one available 
measurement, where both measurements were missing we excluded the woman from the analysis 
of this EM.  For the majority of EMs there were no missing values. For four EMs (2-hydroxyestrone 
(2-OHE1), 2-methoxyestradiol (2-MeOE2), 2-hydroxyestrone-3-methyl ether (3-MeOE1) and 16-
ketoestradiol (16-ketoE2)) there were <10% missing values (Supplementary Table 3). For two EMs (4-
methoxyestrone (4-MeOE1) and 4-methoxyestradiol (4-MeOE2)) levels were undetectable in the 
majority of samples (92 (76.7%) and 107 (89.2%) for 4-MeOE1 and 4-MeOE2, respectively). These two 
EMs were excluded from further analysis. For the 12 EMs that we were able to measure, we 
estimated the within woman variation based on the two sequential samples per woman; intra-class 
correlation coefficients (ICCs) for individual EMs and grouped EMs are shown in Supplementary 
Table 4.  
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For individual and pathway EMs we calculated geometric means and 95% confidence intervals (CIs) 
on the natural logarithm scale and exponentiated the values back to the original scale. Linear 
regression models of the loge transformed EMs were used to estimate percent differences between 
CYP3A7*1C carriers and non-carriers for individual and pathway EMs. We carried out unadjusted 
analyses and analyses that were adjusted for measurement batch (1 -6), body mass index (BMI; 
quartiles), age at first full term pregnancy (quartiles) and parity (0, 1-2, >2). Adjustment for these 
covariates did not alter effect sizes substantially and, therefore, unadjusted results are presented. 
We used t tests of the linear regression coefficient to estimate P values. We applied a Bonferroni 
correction to establish a statistical significance level of P < 0.003, based on our measuring of 14 
individual EMs and five grouped EMs. Statistical analyses were carried out using R (version 3.2.3; 
http://cran.r-project.org). All reported P values are two-sided. 
 
Results 
Characteristics of the 60 women who were included in this analysis are presented in Table 1; there 
were no differences between CYP3A7*1C carriers and non-carriers. Levels of EMs in CYP3A7*1C 
carriers and non-carriers are shown in Figure 2 (full details of individual EMs, grouped EMs and ratios 
of EMs are in Supplementary Table 3). The predominant estrogen/EMs were estriol (E3), E1 and 2-
hydroxyestrone (2-OHE1) with geometric mean concentrations in non-carriers of 63.6, 28.6 and 21.8 
pmol/mg creatinine respectively. The least abundant EMs were the methylated 2-catechol EMs, 2-
methoxyestradiol (2-MeOE2) and 2-Hydroxyestrone-3-methyl ether (3-MeOE1) and 17-Epiestriol (17-
epiE3) with geometric mean concentrations in non-carriers of 0.67, 0.74 and 0.31 pmol/mg 
creatinine, respectively. Levels of the methylated 4-catechol EMs, 4-methoxyestrone (4-MeOE1) and 
4-methoxyestradiol (4-MeOE2) were below the limits of detection in 92 (76.7%) and 107 (89.2%) of 
the 120 samples that we assayed. 
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Comparing CYP3A7*1C carriers to non-carriers, levels of the parent estrogen E1 were 45.3% lower in 
CYP3A7*1C carriers (P = 0.0005, Table 2). For the 2 catechol EMs (2-OHE1 and 2-OHE2) and the 
methylated 2 catechol EMs (2-MeOE1 and 2-MeOE2) the reduction in urinary levels was more 
extreme; compared with non-carriers levels in CYP3A7*1C carriers were -78.3% (P = 1.1 x 10-12), -
67.9% (P = 2.7 x 10-7), -81.2% (P = 1.9 x 10-12), and -62.8% (P = 0.0009) for 2-OHE1, 2-OHE2, 2-MeOE1 
and 2-MeOE2, respectively (Table 2). By contrast, levels of the 16-pathway EMs were slightly higher 
in CYP3A7*1C carriers, i.e. +25.5% (P = 0.11), +91.6% (P = 0.007) and +160.1% (P = 0.002) higher for 
E3, 16α-hydroxyestrone (16α-OHE1) and 17-epiE3, respectively (Table 2). Adjusting for measurement 
batch, body mass index, age at first full term pregnancy and parity did not alter these results 
substantially (Supplementary Table 5). 
 
EMs from the three different estrogen metabolism pathways (2-hydroxylation, 4-hydroxylation and 
16α-hydroxylation) have been associated with different estrogenic and genotoxic properties (Faupel-
Badger et al, 2010; Ziegler et al, 2015) with a high 2-hydroxylation:16α-hydroxylation pathway ratio, 
generally being considered to be associated with a reduction in breast cancer risk. Comparing 
CYP3A7*1C carriers to non-carriers, the 2-OHE1:16α-OHE1 ratio in carriers (0.39, 95% CI 0.26 to 0.57) 
was significantly lower than the ratio in non-carriers (3.86, 95% CI 2.53 to 5.89; P = 1.0 x 10-11; 
Supplementary Table 3). Similarly, combining all 2-hydroxylation pathway and 16α-hydroxylation 
pathway metabolites the ratio in CYP3A7*1C carriers (0.10, 95% CI 0.07 to 0.13) was much lower 
than the ratio in non-carriers (0.51, 95% CI 0.38 to 0.67; P = 1.7 x 10-9; Supplementary Table 3). 
 
Discussion 
To our knowledge, comprehensive data on urinary EMs in premenopausal women, measured using 
LC-MS have been previously reported in three studies (Eliassen et al, 2012; Eliassen et al, 2009; 
Faupel-Badger et al, 2010; Maskarinec et al, 2012). The first of these was the Nurses’ Health Study II 
(NHS II), a prospective study of North American registered nurses aged 25 – 42 years at recruitment 
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(Eliassen et al, 2012; Eliassen et al, 2009). The second was a population based study of incident 
breast cancer among women of Asian ancestry living in California and Hawaii (Faupel-Badger et al, 
2010) and the third was a randomised trial of the effect of consuming soy foods on hormonal 
outcomes, conducted in women of Caucasian, Native Hawaiian and Asian ancestry and living in 
Hawaii (Maskarinec et al, 2012).  
 
Comparing absolute levels of EMs in our study with those reported by these other studies is not 
straightforward. Levels of individual EMs and all EMs combined may differ between ethnicities 
(Maskarinec et al, 2012) and women from several different ethnicities have been included in the reports 
to date (Asian, (Faupel-Badger et al, 2010); African-American, Asian, Hispanic and Caucasian, (Eliassen 
et al, 2012); Caucasian, Native Hawaiian and Asian, (Maskarinec et al, 2012)). In addition, the 30 non-
carriers that we analysed may not be representative of the general British population as they were 
selected on genotype (with a MAF of 4% we would expect 2.2 CYP3A7*1C carriers in a population-based 
sample of 30 women) and six (20%) were first-degree relatives of breast cancer cases suggesting that 
they may be at higher risk than the general population. Our analysis is based on the average of two 
periovulatory samples, Faupel-Badger and colleagues analysed both non-luteal phase and luteal phase 
samples, whereas the studies reported by Eliassen and colleagues and Maskarinec and colleagues 
focussed on luteal phase samples. There is, however, no evidence that the 2-OHE1:16α-OHE1 ratio differs 
according to the phase of the menstrual cycle (Faupel-Badger et al, 2010). Comparing this ratio across 
studies, the 2-OHE1:16α-OHE1 ratio in our non-carriers (3.9) was similar to the 2-OHE1:16α-OHE1 
ratios reported by Faupel-Badger and colleagues (2.2 and 2.1 in luteal phase and non-luteal phase 
samples, respectively) and by Eliassen and colleagues (4.35) but somewhat lower than the ratios 
reported by Maskarinec and colleagues (8.4 and 13.0 in Asian and non-Asians, respectively).   
 
We have previously demonstrated that the CYP3A7*1C allele is associated with lower levels of 
urinary E1G (Johnson et al, 2016). Here we have demonstrated that CYP3A7*1C carriers have a more 
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pronounced reduction in 2-hydroxylation pathway EMs, increased 16α-hydroxylation pathway EMs 
and markedly reduced two-hydroxylation pathway:16α-hydroxylation pathway ratios as measured 
by the 2-OHE1:16α-OHE1 ratio (0.39 in CYP3A7*1C carriers compared to population estimates of 2.1 
to 13.0) or all 2- and 16α-pathway metabolites combined (0.10 in CYP3A7*1C carriers compared to 
population estimates of 0.90 or 0.96 (Eliassen et al, 2012; Eliassen et al, 2009)). Our data are 
consistent with expression of the fetal CYP3A7 gene in adult carriers of the CYP3A7*1C allele 
resulting in (i) a modest reduction in levels of the parent estrogen E1 and (ii) a specific bias towards 
16α-hydroxylation (which can be catalysed by CYP3A7) over 2- or 4- hydroxylation (which are not 
catalysed by CYP3A7 (Lee et al, 2003)).  
 
In their recent review of estrogen metabolism and breast cancer, Ziegler and colleagues concluded 
that the combined evidence from prospective studies using LC-MS to measure EMs in pre-diagnostic 
serum, plasma and urine was consistent with the hypothesis that enhanced 2-hydroxylation is 
associated with reduced risk of breast cancer (Ziegler et al, 2015). They further concluded that the 
inverse association with enhanced 2-hydroxylation (specifically 2-hydroxylation:16α-hydroxylation 
and 2-hydroxylation:parent estrogens ratios) was independent of the strong positive associations 
between unconjugated estradiol and estrone with postmenopausal breast cancer risk (Ziegler et al, 
2015). Our analysis supports these conclusions if we assume that breast cancer risk in carriers of the 
CYP3A7*1C allele is influenced by two components with opposite effects. Based on the combined 
evidence of prospective studies of premenopausal hormone levels and breast cancer risk, lifetime 
lower levels of E1 and E2 of approximately 45% and 27% in carriers of the CYP3A7*1C allele would be 
predicted to result in a substantial reduction in risk for these individuals. By contrast, an 
unfavourable (reduced) 2-hydroxylation:16α-hydroxylation ratio would be expected to increase risk. 
Our previous analyses demonstrate that the reduction in breast cancer risk for carriers of the rare 
allele of rs10235235 (which is correlated with the CYP3A7*1C allele r2 = 0.25, D’ = 1.0) is very modest 
(heterozygote OR = 0.98, P = 0.2; homozygote OR = 0.80, P = 0.004) (Johnson et al, 2014) consistent 
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with an unfavourable (reduced) 2-hydroxylation:16α-hydroxylation counteracting a potentially more 
substantial beneficial effect of lower levels of parent estrogens.  
 
Strengths of our study include our comprehensive analysis of urinary EMs using HPLC-MS/MS and, 
since genotypes are effectively randomised at birth (Ebrahim & Davey Smith, 2008), our focus on a 
genetic variant (the CYP3A7*1C allele) which minimises the potential for confounding by 
unmeasured environmental factors. There are several limitations to our study; due to the frequency of 
the CYP3A7*1C allele the numbers are small and, given our selection procedure, the non-carriers may not 
be representative of the White British population. Our choice of using two consecutive periovulatory 
samples makes it difficult to compare EM levels in our study with other published reports, which 
have mainly analysed a single luteal phase sample (Eliassen et al, 2012; Eliassen et al, 2009; Faupel-
Badger et al, 2010; Maskarinec et al, 2012).  In addition, we do not have prospective data on 
CYP3A7*1C carrier status, hormone levels and breast cancer risk in large numbers of women and we 
cannot compare breast cancer risk in women with low levels of the parent estrogen E1 according to 
their CYP3A7*1C status (and hence 2-hydroxylation:16α-hydroxylation ratio) directly.   
 
In conclusion, we have demonstrated that the CYP3A7*1C allele has a profound effect on levels of 
the parent estrogen E1 and the ratio of 2-hydroxylation:16α-hydroxylation EMs in premenopausal 
women. To characterise the association between parent estrogens, EMs and subsequent risk of 
breast cancer fully, identification of additional genetic variants that influence parent estrogens and 
particular pathway EMs, and further prospective studies that analyse a broad spectrum of EMs will 
be required.  
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Figure Legends: 
 
Figure 1: Steroid hormone synthesis and endogenous estrogen metabolism in humans.  
The 14 estrogen metabolites (EMs) formed by hydroxylation of parent estrogens (E1 and E2), at the 2, 
4-, and 16α-positions of the carbon ring that were measured are shown within the red box. Enzymes 
(cytochrome P450 (CYPs) and catechol O-methyltransferase (COMT)) involved in estrogen 
metabolism are in red. Estrone glucuronide (E1G), measured in our previous analysis (Johnson et al, 
2012) is an estrone conjugate, present in urine. The E1 measured in this analysis (after hydrolysis of 
glucuronide and sulphate conjugates in the first step of the LC-MS/MS protocol) is highly correlated 
with E1G (Spearman’s correlation, ρ=0.70, P<0.0001). Abbreviations: E1= estrone, E2= estradiol, 2-
OHE1=2-hydroxyestrone, 2-OHE2= 2-hydroxyestradiol, 2-MeOE1= 2-methoxyestrone, 2-MeOE2= 2-
methoxyestradiol, 3-MeoE1= 2-hydroxyestrone-3-methyl ether, 4-OHE1= 4-hydroxyestrone, 4-
MeOE1= 4-methoxyestrone, 4-MeOE2= 4-methoxyestradiol, 16α-OHE1= 16α-hydroxyestrone, E3= 
estriol, 16-KetoE2= 16-ketoestradiol, 17-epiE3= 17-epiestriol and  17ß-HSD = 17ß-hydroxysteroid. 
 
Figure 2: Geometric mean levels (picomoles/mg creatinine) of 12 EMs that we measured in urine 
samples from 60 premenopausal women; 30 carriers of the CYP3A7*1C allele (light grey) and 30 
non-carriers (dark grey). Estimates are the average of two samples per woman, taken on sequential 
days, calculated to be at or around ovulation based on the woman’s usual menstrual cycle length. 
Error bars represent standard errors. Levels of two of the 4-hydroxylation pathway EMs (4-MeOE1 
and 4-MeOE2) were below detection in 92 (4-MeOE1) and 107 (4-MeOE2) of the samples analysed. 
These two EMs were, therefore, excluded. 
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Table 1. Characteristics of the 30 CYP3A7*1C carriers and 30 CYP3A7*1C non-carriers included in this 
analysis. 
 CYP3A7*1C non-
carriers 
CYP3A7*1C 
carriers 
P value 
Age at urine collection 44.1 (16 – 53) 45.5 (27– 50) 0.38 
BMI at urine collection 24.0 (19.2 – 39.9) 25.5 (18.3 – 39.0) 0.64 
Parity  
Nulliparous 10 (33.3) 6 (20.0)  
1-2 children 17 (56.7) 15 (50.0)  
>2 children 3 (10.0) 9 (30.0) 0.13 
Age at first full term pregnancy# 26.3 (20 – 31) 27.2 (17 – 32) 0.39 
#in parous women. For quantitative traits (age at urine collection, BMI at urine collection and age at 
first full term pregnancy) means and ranges are presented. For parity, the number and percentage of 
women in each category is shown. For quantitative traits P values were from t tests; for parity the P 
value was from a Fisher’s exact test. 
 
1 
 
Table 2: Percentage difference (95% CI) in urinary EM levels comparing CYP3A7*1C carriers with 
non-carriers 
Grouped EM Individual EM % Difference in EM#$ 
 (95% CI) 
P 
 
Total EMs  -15.1 (-32.7, 7.0) 0.16 
Parent EMs  -41.0 (-57.2, -18.5) 0.002 
 Estrone -45.3 (-60.6, -24.1) 0.0005
 Estradiol -26.7 (-47.5, 2.2) 0.07 
Catechol EMs  -71.0 (-80.1, -57.9) 1.2 x 10-8
2-Catechol EMs  -76.1 (-83.0, -66.6) 8.4 x 10-12
 2-Hydroxyestrone* -78.3 (-84.5, -69.6) 1.1 x 10-12
 2- Hydroxyestradiol -67.9 (-78.3, -52.6) 2.7 x 10-7
4-Catechol EMs   
 4-Hydroxyestrone -51.8 (-72.9, -14.2) 0.01 
Methylated Catechol EM   
Methylated 2-Catechol EM  -73.5 (-81.2, -62.7) 1.9 x 10-10
 2-Methoxyestrone -81.2 (-87.1, -72.6) 1.9 x 10-12
 2-Methoxyestradiol* -62.8 (-78.9, -34.7) 0.0009
 2-Hydroxyestrone-3-methyl ether* -21.9 (-50.3, 22.6) 0.28 
Methylated 4-Catechol EMs   
 4-Methoxyestrone n/a n/a 
 4-Methoxyestradiol n/a n/a 
2-Hydroxylation pathway EMs -74.9 (-81.6, -65.8) 1.6 x 10-12
4-Hydroxylation pathway EMs -51.8 (-72.9, -14.2) 0.01 
16-Hydroxylation pathway EMs 34.7 (1.6, 78.5) 0.04 
 16α-Hydroxyestrone 91.6 (20.2, 205.1) 0.007 
 17-Epiestriol 160.1 (46.0, 363.4) 0.002 
 Estriol 25.5 (-5.1, 66.0) 0.11 
 16-Ketoestradiol* 62.4 (8.7, 142.7) 0.02 
# unadjusted analysis; $a negative difference may be interpreted as lower levels in CYP3A7*1C carriers 
compared to non-carriers; *missing values: 2-OHE2, 1 sample (non-carrier); 2-MeOE2, 11 samples (11 women, 
2 non-carriers, 9 carriers); 3-MeOE1, 11 samples (9 women, 2 non-carriers, 7 carriers), 16-ketoE2, 5 samples (3 
women, 2 non-carriers, 1 carrier). n/a = not available 
 
 
